Comparing two treatments for recurrent Clostridioides difficile infection
Official title: Comparison of defined live biotherapeutic product and fecal microbiota transplantation for treatment of recurrent Clostridioides difficile infection
Funded at Icahn School of Medicine at Mount Sinai · NIH-10845658 · Data updated 2026-11-12
This study is looking at how well a special live treatment works compared to a stool transplant for people who keep getting C. difficile infections, to see if it can help them feel better and improve their gut health in a safer way.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 1, 2022 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $324,480 |
| NIH project number | 5R01DK130337-03 |
| Project ID | NIH-10845658 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing recurrent Clostridioides difficile infections who have not responded to standard antibiotic treatments.
✕Less likely to help
Patients with a single episode of Clostridioides difficile infection or those who have contraindications for either treatment may not benefit from this research.
What this research studies
This research investigates the effectiveness of a defined live biotherapeutic product (LBP) compared to fecal microbiota transplantation (FMT) for treating recurrent Clostridioides difficile infection (rCDI). The study aims to assess how well these treatments work and how they affect the gut microbiome. Patients will receive either the LBP or FMT, and their clinical responses and microbial changes will be closely monitored. This approach seeks to provide a safer and more standardized treatment option for rCDI.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and safer treatment for patients suffering from recurrent Clostridioides difficile infections.
How similar studies have gone: Previous research has shown that fecal microbiota transplantation is effective for treating rCDI, but this approach using defined live biotherapeutic products is relatively novel.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Faith, Jeremiah James — Icahn School of Medicine at Mount Sinai
- Study coordinator: Faith, Jeremiah James
Related research
Other NIH-funded projects on the same topics.
-
Fecal transplant plus fiber to treat graft-versus-host disease after blood stem cell transplant
A study to see if giving fecal transplant along with dietary fiber helps gut health and reduces complications in patients who have received a stem cell transplant and developed graft-versus-host disease.
-
Proteolytic Activity-Guided Fecal Microbiota Transplant for PI-IBS
A pilot study will test a targeted fecal microbiota transplant to help adults with post-infection irritable bowel syndrome feel better and have fewer GI symptoms.
-
Fecal microbiota transplantation plus immune checkpoint blockers for solid tumors
This project looks at whether changing gut bacteria with fecal transplants can boost how well cancer treatments called immune checkpoint blockers work in people with solid tumors.
-
Fecal transplant treatment for auto-brewery (gut fermentation) syndrome
This project gives capsule fecal microbiota transplants to adults with auto-brewery syndrome to try to stop their gut from producing alcohol and causing unexplained intoxication.
-
A new way to use gut bacteria transplants for Irritable Bowel Syndrome
This research explores if a special type of fecal microbiota transplant, guided by specific gut enzyme activity, can safely and effectively improve symptoms for adults with Irritable Bowel Syndrome that developed after an infection.
-
Using gut bacteria to improve cancer treatment for solid tumors
This research explores if changing gut bacteria through fecal microbiota transplantation can help immune checkpoint medicines work better for people with solid tumors.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.